• February 2023: Oxford Nanopore Technologies announced the extension of its collaboration with UPS Healthcare to accelerate the delivery of Oxford Nanopore DNA/RNA sequencing products and consumables across the Asia Pacific region.

• August 2022: a research team from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) developed a genome toolkit, the TMC-SNPdb2.0, comprising a complete dataset of genome sequences of 1,800 individuals, to analyze the cancer-specific gene mutations in the Indian population. The bioinformatics toolkit is aimed to bridge the gap in the availability of Indian-origin cancer genome data in global genomic datasets.

In this report, the Global Genomics in Cancer Care Market has been segmented by Product Type, Technology, Cancer Type, Application, and Geography.

Global Genomics in Cancer Care Market, Segmentation by Product Type

The Global Genomics in Cancer Care Market has been segmented by Product Type into Instruments, Consumables, and Services.

The instruments segment plays a vital role in cancer genomics, accounting for approximately 35% of the global market. These tools are integral for DNA sequencing, microarray analysis, and PCR technologies that enable detailed genetic profiling. The rising adoption of automated systems and technological advancements has significantly improved the speed and accuracy of genomic analysis in cancer diagnostics.

Consumables, including reagents, assay kits, and other lab supplies, make up nearly 40% of the market share. Their repeated use in testing and high demand for sample processing have made them indispensable in genomic workflows. The continuous need for reliable, high-quality consumables is driven by the increasing number of cancer screening and diagnostic procedures worldwide.

The services segment contributes around 25% to the market and encompasses data analysis, bioinformatics, and personalized genomic consulting. With the surge in precision oncology, there is a growing reliance on external service providers to manage large-scale genomic datasets. These services enhance decision-making by translating raw data into actionable clinical insights.

Global Genomics in Cancer Care Market, Segmentation by Technology

The Global Genomics in Cancer Care Market has been segmented by Technology into PCR, MicroArrays, Genome Sequencing, and Others.

PCR (Polymerase Chain Reaction) technology holds approximately 30% share in the genomics-based cancer care market. It is widely used for amplifying DNA sequences, enabling rapid and precise cancer diagnostics. The growing demand for real-time PCR and digital PCR is driving innovation and adoption in early cancer detection.

MicroArrays contribute about 20% to the market and are crucial for gene expression profiling and mutation analysis. This technology is particularly useful in identifying cancer-specific biomarkers. Advances in high-throughput analysis and multiplexing capabilities are boosting its utility in oncogenomics research.

Genome Sequencing leads the market with around 40% share, revolutionizing personalized medicine by providing comprehensive genetic insights. Techniques like next-generation sequencing (NGS) and whole genome sequencing offer unparalleled accuracy in identifying mutations and guiding treatment plans. Their growing affordability is accelerating integration into routine cancer care.

The Others category, covering technologies such as CRISPR, FISH, and Nanopore sequencing, accounts for approximately 10% of the market. These emerging solutions enhance precision and expand the scope of cancer genomics. The increasing application of innovative molecular tools is contributing to the diversification of the genomic diagnostics landscape.

Global Genomics in Cancer Care Market, Segmentation by Cancer Type

The Global Genomics in Cancer Care Market has been segmented by Cancer Type into Breast Cancer, Lung Cancer, and Colorectal Cancer.

Breast cancer dominates the genomics in cancer care market, representing nearly 45% of the total segment. Genomic technologies are widely applied to detect BRCA mutations, evaluate HER2 status, and guide hormonal and targeted therapies. The high incidence rate of breast cancer and the growing trend toward personalized treatment plans drive demand for advanced genomic tools.

Lung cancer accounts for approximately 30% of the genomics market segment, primarily driven by the need for EGFR, ALK, and KRAS mutation testing. Early diagnosis through genomic profiling helps in determining immunotherapy suitability and improving survival outcomes. The increasing prevalence of non-small cell lung cancer (NSCLC) fuels further adoption of precision genomics.

Colorectal cancer contributes around 25% to the market, with genomics used extensively for microsatellite instability (MSI) and KRAS/BRAF mutation testing. These genomic markers are essential for choosing chemotherapy regimens and targeted biologics. The integration of liquid biopsy techniques is also enhancing non-invasive diagnostics in this cancer type.

Global Genomics in Cancer Care Market, Segmentation by Application

The Global Genomics in Cancer Care Market has been segmented by Application into Diagnostics, Personalized Medicine, Drug Discovery Development, Research.

Diagnostics holds the largest share, accounting for approximately 40% of the genomics in cancer care market. Genomic tools are pivotal for early detection, mutation analysis, and cancer classification, significantly improving treatment outcomes. The increasing use of non-invasive testing methods like liquid biopsy further strengthens the role of genomics in diagnostics.

Personalized medicine constitutes about 30% of the application segment, driven by the demand for tailored treatment plans based on individual genetic profiles. Genomic data helps clinicians predict drug responses and select targeted therapies. The push toward precision oncology is accelerating the adoption of genomics in patient-specific cancer management.

Drug discovery and development represents roughly 20% of the market. Genomics enables the identification of novel drug targets and facilitates the development of biomarker-based therapies. It plays a critical role in pharmacogenomics, helping reduce development costs and time by streamlining clinical trials.

Research applications make up around 10% of the market, encompassing academic and institutional efforts to explore genetic mutations, cancer pathways, and resistance mechanisms. Advances in high-throughput sequencing and bioinformatics have significantly enhanced the scope of cancer genomics research.

Global Genomics in Cancer Care Market, Segmentation by Geography

In this report, the Global Genomics in Cancer Care Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Genomics in Cancer Care Market Share (%), by Geographical Region, 2023

North America leads the genomics in cancer care market with a dominant share of approximately 40%. This is fueled by advanced healthcare infrastructure, strong R&D investments, and widespread adoption of personalized medicine. The presence of key industry players and favorable reimbursement policies further support market growth in this region.

Europe holds about 25% of the market, driven by increasing government funding and public-private partnerships for genomic research. Countries like Germany, the UK, and France are at the forefront of integrating genomic diagnostics into standard cancer care. Strong regulatory support and growing awareness are key growth enablers.

Asia Pacific is rapidly emerging, accounting for around 20% of the market. Rising cancer prevalence, expanding healthcare access, and increased investments in genomic technologies are contributing factors. Countries like China, Japan, and India are heavily investing in precision oncology and genome mapping initiatives.

Middle East and Africa make up roughly 8% of the market, supported by improving healthcare infrastructure and growing interest in early cancer detection. While still in early stages, nations like the UAE and South Africa are increasingly adopting genomic solutions to address regional cancer burdens.

Latin America represents about 7% of the market, with Brazil and Mexico leading in adoption. Increasing focus on biomarker research, along with partnerships between global and local healthcare entities, is driving the integration of genomics in cancer diagnostics and treatment across the region.